Assessment of P-glycoprotein Activity in the Blood-Brain Barrier (BBB) Using Near Infrared Fluorescence (NIRF) Imaging Techniques

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2011 May 21

PMID 21598079

Citations 12

Authors

Ngoc H On

Fang Chen

Martha Hinton

Donald W Miller

Affiliations

Soon will be listed here.

Abstract

Purpose: To examine functional activity of P-glycoprotein (P-gp) in the blood-brain barrier (BBB) using near infrared fluorescence (NIRF) imaging techniques.

Methods: Cellular accumulation and bi-directional permeability of the NIRF probe, rhodamine 800 (R800) was determined in MDCKMDR1 and MDCKwt monolayers under normal conditions and following P-gp inhibition with GF120918. Functional P-gp activity was also assessed in mice following administration of R800 alone and with GF230918. Quantitative analysis of R800 fluorescence in brain tissue and blood was measured ex-vivo using Odyssey Near Infrared imaging.

Results: R800 accumulation was reduced in MDCKMDR1 compared to MDCKwt monolayers. Addition of GF120918, resulted in increased R800 accumulation in MDCKMDR1 monolayers. Permeability of R800 in MDCKMDR1 monolayers was significantly enhanced (4-fold) in the basolateral to apical direction under control conditions and was abolished following treatment with GF120918. With the exception of the choriod plexus, there was very little penetration of R800 into the brain under control conditions. Treatment of mice with GF120918 resulted in a nearly 4-fold increase in R800 fluorescence in the brain. In contrast, GF120918 had no effect on brain penetration of a vascular permeability marker.

Conclusions: In vitro studies demonstrate the P-gp transporter properties of the NIRF probe R800. Preliminary in vivo studies confirm the P-gp transporter liabilities of R800 and suggest this probe may be useful as a molecular imaging agent for examining P-gp activity in the BBB.

Citing Articles

Regulation of P-Glycoprotein during Oxidative Stress.

Shchulkin A, Abalenikhina Y, Kosmachevskaya O, Topunov A, Yakusheva E Antioxidants (Basel). 2024; 13(2).

PMID: 38397813 PMC: 10885963. DOI: 10.3390/antiox13020215.

Modulation of Wnt/β-catenin signaling promotes blood-brain barrier phenotype in cultured brain endothelial cells.

Laksitorini M, Yathindranath V, Xiong W, Hombach-Klonisch S, Miller D Sci Rep. 2019; 9(1):19718.

PMID: 31873116 PMC: 6928218. DOI: 10.1038/s41598-019-56075-w.

Evaluation of Near Infrared Dyes as Markers of P-Glycoprotein Activity in Tumors.

Semenenko I, Portnoy E, Aboukaoud M, Guzy S, Shmuel M, Itzhak G Front Pharmacol. 2016; 7:426.

PMID: 27895581 PMC: 5108765. DOI: 10.3389/fphar.2016.00426.

Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-Glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis.

Qosa H, Lichter J, Sarlo M, Markandaiah S, McAvoy K, Richard J Glia. 2016; 64(8):1298-313.

PMID: 27158936 PMC: 5541958. DOI: 10.1002/glia.23003.

Comparison of Linear and Cyclic His-Ala-Val Peptides in Modulating the Blood-Brain Barrier Permeability: Impact on Delivery of Molecules to the Brain.

Alaofi A, On N, Kiptoo P, Williams T, Miller D, Siahaan T J Pharm Sci. 2016; 105(2):797-807.

PMID: 26869430 PMC: 4756412. DOI: 10.1016/S0022-3549(15)00188-4.

References

Urquhart B, Kim R . Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol. 2009; 65(11):1063-70. DOI: 10.1007/s00228-009-0714-8. View

Dorner B, Kuntner C, Bankstahl J, Bankstahl M, Stanek J, Wanek T . Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem. 2009; 52(19):6073-82. PMC: 3690441. DOI: 10.1021/jm900940f. View

Giacomini K, Huang S, Tweedie D, Benet L, Brouwer K, Chu X . Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3):215-36. PMC: 3326076. DOI: 10.1038/nrd3028. View

Girardin F . Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin Neurosci. 2006; 8(3):311-21. PMC: 3181821. View

Choy G, Choyke P, Libutti S . Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging. 2004; 2(4):303-12. DOI: 10.1162/15353500200303142. View

Martin C, Berridge G, Higgins C, Callaghan R . The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction. Br J Pharmacol. 1998; 122(4):765-71. PMC: 1564986. DOI: 10.1038/sj.bjp.0701429. View

Bachmeier C, Spitzenberger T, Elmquist W, Miller D . Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res. 2005; 22(8):1259-68. DOI: 10.1007/s11095-005-5271-y. View

Bachmeier C, Trickler W, Miller D . Comparison of drug efflux transport kinetics in various blood-brain barrier models. Drug Metab Dispos. 2006; 34(6):998-1003. DOI: 10.1124/dmd.105.006999. View

Dombrowski S, Desai S, Marroni M, Cucullo L, Goodrich K, Bingaman W . Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia. 2002; 42(12):1501-6. DOI: 10.1046/j.1528-1157.2001.12301.x. View

10.

Jonker J, Wagenaar E, van Deemter L, Gottschlich R, Bender H, Dasenbrock J . Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br J Pharmacol. 1999; 127(1):43-50. PMC: 1565984. DOI: 10.1038/sj.bjp.0702497. View

11.

Shaik N, Giri N, Pan G, Elmquist W . P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos. 2007; 35(11):2076-85. DOI: 10.1124/dmd.107.017723. View

12.

Pekcec A, Unkruer B, Stein V, Bankstahl J, Soerensen J, Tipold A . Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus. Epilepsy Res. 2008; 83(2-3):144-51. DOI: 10.1016/j.eplepsyres.2008.10.010. View

13.

Wang Q, Yang H, Miller D, Elmquist W . Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun. 1995; 211(3):719-26. DOI: 10.1006/bbrc.1995.1872. View

14.

Kaijzel E, van der Pluijm G, Lowik C . Whole-body optical imaging in animal models to assess cancer development and progression. Clin Cancer Res. 2007; 13(12):3490-7. DOI: 10.1158/1078-0432.CCR-07-0402. View

15.

Matsuoka Y, Okazaki M, Kitamura Y, Taniguchi T . Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain. J Neurobiol. 1999; 39(3):383-92. DOI: 10.1002/(sici)1097-4695(19990605)39:3<383::aid-neu5>3.0.co;2-4. View

16.

Zidan A, Spinks C, Fortunak J, Habib M, Khan M . Near-infrared investigations of novel anti-HIV tenofovir liposomes. AAPS J. 2010; 12(2):202-14. PMC: 2844515. DOI: 10.1208/s12248-010-9177-1. View

17.

Lee C, Cook J, Reyner E, Smith D . P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol. 2010; 6(5):603-19. DOI: 10.1517/17425251003610640. View

18.

Polli J, Wring S, Humphreys J, Huang L, Morgan J, Webster L . Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001; 299(2):620-8. View

19.

Rao V, Dahlheimer J, Bardgett M, Snyder A, Finch R, Sartorelli A . Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A. 1999; 96(7):3900-5. PMC: 22392. DOI: 10.1073/pnas.96.7.3900. View

20.

Miller D, Fontain M, Kolar C, Lawson T . The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett. 1996; 107(2):301-6. DOI: 10.1016/0304-3835(96)04384-4. View